Healio23h
Lifestyle changes plus drug therapy inferior to catheter ablation in AF, obesity
For patients with atrial fibrillation and obesity, lifestyle modification plus antiarrhythmic drug therapy conferred various ...
PharmiWeb6h
J&J MedTech Unveils Promising 12-Month Data on Dual Energy Ablation Technology at EHRA 2025
Congress, Johnson & Johnson MedTech presented pivotal 12-month safety and effectiveness data from the SmartfIRE study—offering new insights into the future of atrial fibrillation (AFib) treatment. The ...
MedPage Today2h
Runners' Cardiac Toll Down; IABP Flop in Cardiogenic Shock; Progress on Oral PCSK9i
The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...
Handpicked solutions for all your healthcare needs
This 2025 guide features leading specialists in geriatrics, cardiology, oncology, cosmetic dentistry and cutting-edge ...
Le Lézard4h
Heart Rhythm Case Reports Publishes Notable Case Detailing First Use of AI-Guided ECG Mapping for Left Bundle Branch Area Pacing
Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the publication of a groundbreaking case in Heart Rhythm Case Reports. Conducted by physicians from ...
PharmiWeb9h
Johnson & Johnson MedTech Presents Pivotal 12-Month Effectiveness and Safety Data from SmartfIRE Study at 2025 EHRA Congress
SmartfIRE 12-month data demonstrated 86.9% effectiveness when utilized with high adherence to the recommended ablation workflow and significant quality of life improvements using the Dual Energy ...
Cryofocus Medtech (Shanghai) Co., Ltd.: Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Nearly 10 Product Candidates Under Development are Expected to be Commercialized in the Next Three YearsHONG KONG, Apr 1, 2025 - (JCN Newswire) - Cryofocus Medtech (Shanghai) Co., Ltd. ('Cryofocus Med ...